SCHEDULE: Foresite Capital Discloses 5.1% Stake in CASI Pharma

Foresite Capital entities and James Tananbaum report beneficial ownership of 5.1% of CASI Pharmaceuticals, Inc.'s Ordinary Shares.

Summary

• Foresite Capital Fund VI, L.P., Foresite Capital Management VI, LLC, and James Tananbaum collectively reported beneficial ownership of 787,121 Ordinary Shares of CASI Pharmaceuticals, Inc.
• This ownership represents 5.1% of the Issuer's Ordinary Shares outstanding.
• The percentage is calculated based on 15,492,581 Ordinary Shares outstanding as of December 31, 2024, as reported in CASI Pharmaceuticals, Inc.'s Form 20-F filed on March 31, 2025.
• The reporting persons, including Foresite Capital Fund VI, L.P., Foresite Capital Management VI, LLC, and James Tananbaum, each hold sole voting and dispositive power over these 787,121 shares.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of beneficial ownership. The maintenance of a significant 5.1% stake by a notable institutional investor like Foresite Capital can be viewed as a moderately positive signal of continued confidence in the company, though it does not provide new operational or financial performance data.

Positives

• A significant institutional investor, Foresite Capital, maintains a 5.1% beneficial ownership stake, indicating continued interest in CASI Pharmaceuticals, Inc.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an institutional investor in a pharmaceutical company. Such disclosures provide transparency regarding significant stakes held by investment funds, which can be a signal of investor confidence or strategic interest within the highly capital-intensive and research-driven pharmaceutical industry.

Comparison to Industry Standards

• The 5.1% stake held by Foresite Capital is a material ownership percentage, exceeding the 5% threshold that mandates public disclosure under SEC rules. This level of ownership is common for institutional investors taking significant positions in smaller to mid-cap biotechnology or pharmaceutical companies, such as those often found in the portfolios of specialized healthcare funds like Foresite Capital.
• While specific comparable companies or projects are not detailed in this filing, a 5.1% stake suggests a notable, but not controlling, interest, aligning with typical passive investment strategies for Schedule 13G filers.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence investor sentiment and perception of stability.
• Regulatory Authorities: Fulfills SEC disclosure requirements for beneficial ownership, ensuring market transparency.

Key Dates

Keywords

CASI Pharmaceuticals, Foresite Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Ordinary Shares, Institutional Investor, Biotechnology, Pharmaceuticals